patent.fyi
Applications  /  US 2026/0355177
United States Patent Application Publication

US 2026/0355177 A1

Published
Nov 12, 2026
Filed
Jul 31, 2023
Earliest date on the face
Aug 1, 2022
Classification
A61K 31/4704
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

No entries.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Paired exposure in veterinary marrow research

Primary canine marrow cells are cultured in multiwell plates for veterinary hematology research. Separate wells receive a prolyl hydroxylase inhibitor, a thrombopoietin receptor agonist, both agents, or vehicle. An agonist-only control with a receptor signaling readout measures activity in canine cells. Imaging and cell counts track erythroid and megakaryocyte maturation across the exposure groups.

Component substitution

Peptide agonist in a marrow assay

A receptor-activating peptide replaces the small-molecule thrombopoietin receptor agonist in a two-agent cell assay. The peptide and the prolyl hydroxylase inhibitor are prepared in separate stock solutions and added to the same culture wells. The assay measures STAT5 phosphorylation for receptor signaling and intracellular hypoxia-inducible factor accumulation for prolyl hydroxylase inhibition.

Parameter or scale variation

Two-agent concentration matrix in microplates

A 96-well plate holds a 6-by-6 concentration matrix for a prolyl hydroxylase inhibitor and a thrombopoietin receptor agonist. Each axis contains a zero concentration and five concentrations spaced by twofold dilution. The 36 conditions are run in duplicate at the same final vehicle concentration. After 72 hours, the assay records viable cell counts and lineage marker frequencies for each condition.

Staggered addition in marrow cell cultures

Parallel marrow culture wells receive the inhibitor and agonist together or receive the inhibitor 24 hours before the agonist. The simultaneous group receives both agents at hour 24, and the staggered group retains the inhibitor when the agonist is added. Vehicle and single-agent wells receive matching additions at hours 0 and 24. The assay measures viability and lineage markers at hour 72.

Combination with existing systems

Paired exposure in a perfused marrow chip

A microfluidic marrow culture chip contains a porous scaffold seeded with hematopoietic progenitors and stromal cells. Two syringe pumps feed the inhibitor and agonist from separate reservoirs into a mixing junction upstream of the scaffold. A matched chip receives vehicle at the same total flow rate. Outlet samples provide measurements of soluble markers over time, and imaging tracks cells retained in the scaffold.

Automated or data-driven variant

Automated dispensing and lineage cell counts

A liquid handler reads a plate map and dispenses the inhibitor and agonist into wells from separate source plates. An automated microscope captures fluorescence images of nuclei and erythroid and megakaryocyte markers at fixed intervals. Image analysis software segments nuclei and applies marker thresholds established from control wells. The software links the resulting cell counts to each well's exposure conditions.

Cite aspatent.fyi, US 2026/0355177 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355177/, SHA-256 db1ca351c604dc13fa4cebf9223eba30b0088aa4b8102d4b228c9f00db0822a8
First published
Permanent addresshttps://patent.fyi/US20260355177/
Content fingerprint (SHA-256)db1ca351c604dc13fa4cebf9223eba30b0088aa4b8102d4b228c9f00db0822a8
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi